African American men experience significant health disparities. They are almost twice as likely to be diagnosed with prostate cancer as white men, yet they are underrepresented in prostate cancer research. A new study by Charles R. Rogers, PhD, MPH, MS, CHES®, uncovers attitudes toward prostate cancer research among African American men and suggests strategies to increase participation in research. The study is included in a new collection of research on health disparities impacting African American men.
health equity News
The PathMaker program is a stepping stone for students interested in a career in health sciences or STEM with backgrounds underrepresented in the biomedical workforce.
The second cancer conference for the Hispanic/Latino Community of Utah, Salud Para Mí, Es Salud Para Mi Familia 2018, took place Saturday, June 16, at Salt Lake Community College. The conference offers a space for the Hispanic/Latino community of Utah to receive screenings with local health care providers, get reliable health information, and learn about cancer screening and prevention.
Huntsman Cancer Institute Opens Center for HOPE and is Awarded $9.7 Million to Improve Health Among Underserved Populations
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) today announced the opening of the Cancer Population Sciences and Huntsman Center for Health Outcomes and Population Equity (HOPE), a new research and clinical space dedicated to preventing cancer and improving health among underserved populations and improving outcomes in cancer patients. The center recently received $9.7 million from the Patient-Centered Outcomes Research Institute (PCORI) to fund a clinical trial researching new and effective approaches to reduce tobacco use.
The Immortal Life of Henrietta Lacks is an acclaimed nonfiction book about the revolutionary research, ethical questions, and racism wrapped up in one woman’s cancer story.
The PathMaker Cancer Research Program is for high school and undergraduate students with backgrounds underrepresented in the biomedical workforce. Under the mentorship of an HCI scientist, PathMaker scholars conduct research and build a foundation for careers in health professions and biomedical research.
This year’s conference provided a unique opportunity for the Spanish-speaking community of Utah to learn about cancer and interact with local health care providers.
Kali Dale, a graduate research assistant at HCI, was selected to receive the National Cancer Institute Graduate Diversity Supplement.
The information we use to make health decisions can be conflicting, overwhelming, and hard to understand. Our ability to make decisions based on this information is called "health literacy."
As we all strive towards health equity, a cornerstone value for Huntsman Cancer Institute and University of Utah Health, we invite you to join opportunities this April for National Minority Health Month.
April 3-9 is National Public Health Week, which celebrates a growing movement to create the healthiest nation we can. The public health system prevents diseases, including cancer. Public health officials look for patterns to understand why cancer and other diseases happen, teach people about healthy decisions, and create policies that make sure we live in healthy, safe communities.
Mary Beckerle, PhD, CEO of Huntsman Cancer Institute, served as a panelist at an event organized by the White House Cancer Moonshot Task Force. Beckerle participated in a discussion on addressing disparities in access to cancer prevention, diagnosis, and treatment.
Huntsman Cancer Institute (HCI) at the University of Utah participated in a national summit on the Cancer Moonshot initiative on June 29, 2016. The Cancer Moonshot Summits were organized at the request of Vice President Joe Biden, and more than 270 organizations hosted summits that brought together patients and survivors, researchers, physicians, advocates, philanthropists, and data and technology experts to brainstorm ways of speeding up progress in cancer prevention, diagnosis, treatment, and care over the next five years—and to ultimately end cancer as we know it.